One of the most important developments in breast cancer, especially for people with hormone receptor-positive (HR+) advanced ...

An affordable new BRCA gene test has hit the market, but who should take it? — -- A new genetic testing kit that hits the market today is the most affordable, and arguably one of the simplest, ...

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and ...

Study results indicate that mutation strength may shape both tumor–immune system interactions and immunotherapy response.

Cathy Eng, professor and director, Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, says mutation testing is done to determine which, if any, therapies ...

Scientists have created a complete map showing how hundreds of possible mutations in a key cancer gene influence tumor growth ...

Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

The diagnostics advisory committee reviewed the evidence available on the clinical and cost effectiveness of epidermal growth factor receptor tyrosine kinase (EGFR‑TK) mutation testing to inform first ...

The systematic review was carried out to identify evidence on the technical performance and clinical effectiveness of the different options available to detect epidermal growth factor receptor ...